gilteritinib

Overview

Gilteritinib is a small-molecule targeted therapy used as a FLT3 inhibitor, with established clinical use in relapsed or refractory acute myeloid leukemia (AML) harboring FLT3 mutations. Its therapeutic relevance stems from the central role of FLT3 signaling in leukemic cell survival and proliferation, particularly in FLT3-ITD and related mutant AML subtypes. By inhibiting FLT3, gilteritinib can suppress downstream oncogenic signaling pathways that support leukemic growth.

In recent biomedical research, gilteritinib has also served as a reference FLT3 inhibitor in mechanistic and combination-therapy studies. These investigations have placed it in the context of FLT3-mutant AML, leukemia stem cell targeting, post-transplant maintenance, and resistance biology. Beyond AML, it has been explored experimentally in other cancer settings, including ALK-rearranged non-small-cell lung cancer, where it was studied for effects on resistance-associated signaling such as PD-L1 and CD8 co-expression.

Focus of Latest Publications

Recent publications continue to position gilteritinib as a clinically established FLT3 inhibitor for patients with relapsed or refractory AML carrying FLT3 mutations. One study specifically examined real-world use of gilteritinib as maintenance therapy following allogeneic hematopoietic stem cell transplantation in this patient population, reinforcing its role in post-transplant disease control.

Gilteritinib was also included in a combination strategy aimed at leukemia stem cells in epigenetic mutant AML. In that study, the FLT3 inhibitor was paired with venetoclax, a BCL2 inhibitor, and inobrodib, a P300/CBP inhibitor. The authors noted that venetoclax and gilteritinib are already used upfront in a subset of adult AML patients and can extend survival, but that a curative, low-toxicity combination remains an unmet need. This places gilteritinib within broader efforts to combine FLT3 inhibition with apoptosis-targeting and epigenetic therapies to improve depth of response.

Several studies used gilteritinib as a benchmark compound when evaluating new FLT3-directed agents or delivery systems. In one report, a newly developed compound was described as a type-I FLT3 inhibitor with potency comparable to quizartinib and gilteritinib, but with substantially greater activity against MV4-11 cells, suggesting an additional mechanism beyond FLT3 inhibition. Another study on hydrophobically modified polypeptide nanocarriers showed that gilteritinib-loaded unimolecular micelles improved therapeutic outcomes and significantly limited AML progression in a systemic mouse xenograft model, indicating interest in formulation strategies to enhance delivery and efficacy.

Resistance biology was another major theme. A 2026 pharmacology study on nintedanib reported that this compound had activity against FLT3-ITD and could overcome the gatekeeper F691L resistance mutation in AML; in a Ba/F3 FLT3-ITD-F691L mouse model, nintedanib showed superior anti-leukemic efficacy compared with gilteritinib and quizartinib. This underscores gilteritinib’s role as a comparator in studies of resistance mutations that limit FLT3 inhibitor effectiveness.

Outside AML, gilteritinib was investigated in ALK-rearranged non-small-cell lung cancer, where researchers explored how it might overcome resistance to second-generation tyrosine kinase inhibitors. The study proposed a mechanism involving inhibition of PD-L1 and CD8 co-expression, suggesting immunologic as well as kinase-related effects in that setting. Although this is not its standard clinical indication, it reflects ongoing interest in gilteritinib as a pharmacologic probe for signaling and resistance pathways.

Key Publications

Jun An unprecedented potent inhibitor of MV4-11 cells: investigations into the mechanism of action beyond FLT3 inhibition. (Bioorganic chemistry, 2026, PMID 41671740): "Further studies identified compound 1 as a type-I FLT3 inhibitor with comparable potency to quizartinib and gilteritinib; however, compound 1 is much more potent against MV4-11 cells, indicating that it may have a second molecular mechanism of action independent of FLT3 inhibition."
Jun Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations. (Blood research, 2026, PMID 42230462): "Gilteritinib is an established FLT3 inhibitor used to treat patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) harboring FLT3 mutations."
Jun Modulation of intrabone distribution of anionic polypeptide nanocarriers through hydrophobic modification for the treatment of acute myeloid leukemia. (Acta biomaterialia, 2026, PMID 42025987): "After the size optimization, the gilteritinib-loaded, polypeptide-based unimolecular micelles showed enhanced therapeutic outcomes with significantly limited progression of AML in a systemic mouse xenograft model."
May P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML. (Science advances, 2026, PMID 42139346): "While targeted BCL2 and FLT3 inhibitors venetoclax and gilteritinib are used upfront in the treatment of a subset of adult patients with AML and help to extend the survival of some patients, a curative treatment combination with minimal side effects has yet to be discovered."
May Nintedanib is a potent FLT3 inhibitor with activity against FLT3-ITD and overcomes the gatekeeper F691L resistance mutation in acute myeloid leukemia. (European journal of pharmacology, 2026, PMID 42035942): "In a Ba/F3 FLT3-ITD-F691L mouse model, nintedanib demonstrated superior anti-leukemic efficacy compared with gilteritinib and quizartinib."
May Gilteritinib overcomes second‑generation TKIs resistance in ALK‑rearranged non‑small‑cell lung cancer by inhibiting PD‑L1 and CD8 co‑expression. (International journal of molecular medicine, 2026, PMID 42059267): "The present study investigated how gilteritinib overcomes resistance to second-generation tyrosine kinase inhibitors in anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC), providing new theoretical support for NSCLC treatment."